LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Kodu・Aktsiate loetelu・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Suletud

3.92 -1.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.85

Max

4.08

Põhinäitajad
By Trading Economics
Sissetulek	5.5M -28M
Müük	8.2M 13M
Aktsiakasum	-0.47
Kasumimarginaal	-208.694
Töötajad	172
EBITDA	-1.9M -36M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+219.29% upside

Turustatistika
By TradingEconomics
Turukapital	-18M 237M
Eelmine avamishind	5.18
Eelmine sulgemishind	3.92

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

3.17 / 3.4644 Toetus ja vastupanu

Voyager Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2025, 21:34 UTC

Tulu

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13. nov 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13. nov 2025, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13. nov 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q EPS 52c >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q Sales $22.6B >JBS

13. nov 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13. nov 2025, 22:02 UTC

Tulu

Nu Holdings 3Q Net $783M >NU

13. nov 2025, 22:01 UTC

Tulu

Nu Holdings 3Q Rev $4.2B >NU

13. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13. nov 2025, 21:50 UTC

Tulu

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13. nov 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13. nov 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13. nov 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13. nov 2025, 21:33 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13. nov 2025, 21:31 UTC

Tulu

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q EPS 34c >FIGR

13. nov 2025, 21:23 UTC

Tulu

Intchains Group 3Q Rev $1.3M >ICG

13. nov 2025, 21:03 UTC

Tulu

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13. nov 2025, 21:02 UTC

Tulu

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Rev $6.8B >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Gross Margin 48.0% >AMAT

Võrdlus sarnastega

Hinnamuutus

Voyager Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

219.29% tõus

12 kuu keskmine prognoos

Keskmine 13.57 USD 219.29%

Kõrge 25 USD

Madal 8 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Voyager Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Voyager Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.17 / 3.4644Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.